12:00 AM
Dec 17, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Volasertib: Phase II data

Interim data from the Phase II portion of an open-label, international Phase I/II trial in 87 newly diagnosed AML patients considered ineligible for intensive remission induction therapy showed that IV volasertib plus low-dose cytarabine (LDAC) non-significantly improved the primary endpoint of ORR, defined as complete remission (CR) or complete remission with...

Read the full 234 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >